UBS lowered the firm’s price target on Enhabit (EHAB) to $8.50 from $10 and keeps a Neutral rating on the shares. Enhabit’s Q2 results were largely positive, but the company is focused on combating the home health rate cut, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHAB: